In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial

M A Pfaller; R Hollis; B P Goldstein; S Messer; D Diekema; T Henkel

doi:10.1128/JCM.00806-10

In vitro activity of anidulafungin and other agents against esophageal candidiasis-associated isolates from a phase 3 clinical trial

J Clin Microbiol. 2010 Jul;48(7):2613-4. doi: 10.1128/JCM.00806-10. Epub 2010 May 26.

Authors

M A Pfaller¹, R Hollis, B P Goldstein, S Messer, D Diekema, T Henkel

Affiliation

¹ Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242, USA. michael-pfaller@uiowa.edu

Abstract

The efficacy of anidulafungin, an echinocandin antifungal agent with potent anti-Candida activity, in treating esophageal candidiasis was tested in a double-blind study versus oral fluconazole. Isolates were identified and tested for susceptibility. Candida albicans represented >90% of baseline isolates. The MIC(90) of anidulafungin for all strains was 0.06 mg/liter.

MeSH terms

Anidulafungin
Antifungal Agents / pharmacology*
Candida / drug effects*
Candidiasis / microbiology*
Clinical Trials, Phase III as Topic
Double-Blind Method
Drug Resistance, Fungal
Echinocandins / pharmacology*
Esophageal Diseases / microbiology*
Humans
Microbial Sensitivity Tests

Substances

Antifungal Agents
Echinocandins
Anidulafungin